NEW YORK, March 11, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company, including recent progress and upcoming milestones at the SG Cowen & Co. 25th Annual Health Care Conference in Boston. Mr. Weiss' presentation will take place on Wednesday, March 16, 2005 at 3:10 p.m. Eastern Time in Salon C of the Marriott Copley Place Hotel. A live audio webcast of Mr. Weiss' presentation will be available at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=KERX&item_id=1026068. An archived version of the webcast will be available beginning approximately 1 hour after the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound for the treatment of diabetic nephropathy, which is in a Phase II/III clinical program. Additionally, Keryx is developing clinical-stage oncology compounds including KRX-0401, a novel, first-in-class, oral AKT inhibitor in Phase II clinical trials. Keryx also has an active in- licensing and acquisition program designed to identify and acquire clinical- stage drug candidates. Keryx Biopharmaceuticals is headquartered in New York City.